A detailed history of Ubs Group Ag transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Ubs Group Ag holds 189,194 shares of BEAM stock, worth $5.49 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
189,194
Previous 162,577 16.37%
Holding current value
$5.49 Million
Previous $3.81 Million 21.69%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$22.57 - $33.14 $600,745 - $882,087
26,617 Added 16.37%
189,194 $4.64 Million
Q2 2024

Aug 13, 2024

SELL
$21.22 - $32.66 $1.86 Million - $2.86 Million
-87,664 Reduced 35.03%
162,577 $3.81 Million
Q1 2024

May 13, 2024

SELL
$23.46 - $45.07 $240,676 - $462,373
-10,259 Reduced 3.94%
250,241 $8.27 Million
Q4 2023

Feb 09, 2024

BUY
$17.69 - $30.76 $2.5 Million - $4.34 Million
141,102 Added 118.18%
260,500 $7.09 Million
Q3 2023

Nov 09, 2023

SELL
$23.01 - $32.46 $179,662 - $253,447
-7,808 Reduced 6.14%
119,398 $2.87 Million
Q2 2023

Aug 11, 2023

BUY
$29.32 - $35.99 $2.17 Million - $2.66 Million
73,921 Added 138.73%
127,206 $4.06 Million
Q1 2023

May 12, 2023

SELL
$30.15 - $48.79 $2.58 Million - $4.17 Million
-85,420 Reduced 61.58%
53,285 $1.63 Million
Q4 2022

Feb 08, 2023

BUY
$36.73 - $51.6 $4.79 Million - $6.74 Million
130,546 Added 1600.02%
138,705 $5.42 Million
Q3 2022

Nov 10, 2022

SELL
$39.79 - $70.31 $1.25 Million - $2.21 Million
-31,393 Reduced 79.37%
8,159 $389,000
Q2 2022

Aug 10, 2022

SELL
$29.86 - $62.36 $782,511 - $1.63 Million
-26,206 Reduced 39.85%
39,552 $1.53 Million
Q1 2022

May 16, 2022

BUY
$53.73 - $82.16 $1.46 Million - $2.23 Million
27,174 Added 70.43%
65,758 $3.77 Million
Q4 2021

Feb 14, 2022

SELL
$68.02 - $99.06 $691,559 - $1.01 Million
-10,167 Reduced 20.85%
38,584 $3.08 Million
Q3 2021

Nov 15, 2021

BUY
$84.37 - $133.6 $1.67 Million - $2.64 Million
19,781 Added 68.28%
48,751 $4.24 Million
Q2 2021

Aug 13, 2021

SELL
$64.12 - $128.71 $612,923 - $1.23 Million
-9,559 Reduced 24.81%
28,970 $3.73 Million
Q1 2021

May 12, 2021

BUY
$71.28 - $120.75 $1.2 Million - $2.03 Million
16,773 Added 77.1%
38,529 $3.08 Million
Q4 2020

Feb 11, 2021

BUY
$22.24 - $95.63 $384,640 - $1.65 Million
17,295 Added 387.69%
21,756 $1.78 Million
Q3 2020

Nov 12, 2020

SELL
$19.0 - $30.57 $52,706 - $84,801
-2,774 Reduced 38.34%
4,461 $110,000
Q2 2020

Jul 31, 2020

BUY
$15.26 - $28.66 $98,198 - $184,427
6,435 Added 804.37%
7,235 $203,000
Q1 2020

May 01, 2020

BUY
$13.31 - $29.2 $10,648 - $23,360
800 New
800 $14,000

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $2.04B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.